Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Search by expertise, name or affiliation
BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma
Luca Paoluzzi
, Douglas Hanniford
, Elena Sokolova
, Iman Osman
, Farbod Darvishian
,
Jinhua Wang
, James E. Bradner
, Eva Hernando
Institute for Health Informatics
Office of Academic Clinical Affairs
Masonic Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
43
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
BRAF-mutant Melanoma
100%
Bromodomain and Extra-terminal Domain
100%
BRAF Inhibitor (BRAFi)
100%
Vemurafenib
75%
RNA Sequencing (RNA-seq)
50%
Melanoma Treatment
50%
Drug-treated
50%
Tumor Growth
25%
Cell Proliferation
25%
Molecular Mechanism
25%
Metastatic Melanoma
25%
Epigenetic Regulators
25%
In Vivo Efficacy
25%
Melanoma
25%
Apoptosis
25%
Family Members
25%
Melanoma Cells
25%
Combination Treatment
25%
In Vivo Model
25%
Improved Survival
25%
Cytotoxicity Assay
25%
Anti-apoptotic Proteins
25%
Mutant Cell Line
25%
Tumor Tissue
25%
Proliferation in Vitro
25%
BRAF Inhibition
25%
Xenograft Tumor
25%
Treatment Failure
25%
Apoptotic Genes
25%
In Vitro Growth
25%
Tumor Growth in Vivo
25%
Xenograft Mouse Model
25%
BRAF mutant
25%
Apoptosis Assay
25%
Antibody Array
25%
Combined Treatment
25%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Vemurafenib
60%
RNA-Sequencing
40%
Tumor Growth
40%
Mouse Model
20%
Cytotoxicity Assay
20%
Antiapoptotic
20%
Apoptosis Assay
20%
Metastatic Melanoma
20%
Neoplasm
20%